Alzamend Neuro(ALZN)
ATLANTA, GABiotechnology
Focus: Alzamend Neuro is a public biotech focused on Alzheimer's disease treatment, headquartered in Atlanta with an early-stage pipeline in Phase 1/2 development.
Profile data last refreshed 11h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Alzamend Neuro
AI assessmentNot HiringNo open roles listed right now. Follow Alzamend Neuro to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Alzamend Neuro's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ALZN002
Alzheimer's DiseaseClinical Trials (1)
NCT05834296Study in Subjects With Mild-to-Moderate Alzheimer's Dementia
Phase 1/2Help build intelligence for Alzamend Neuro
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.